Home / M&A Activity / CACI to Buy Health Data Analysis Firm; Dan Allen Comments

CACI to Buy Health Data Analysis Firm; Dan Allen Comments

Dan Allen

CACI International (NYSE: CACI) has agreed to acquire the healthcare data integration and analysis provider Emergint Technologies, with the transaction expected to close Dec. 1.

CACI did not disclose the terms of the deal in its release.

CACI estimates Emergint’s 2012 revenue at around $42 million and expects the transaction to increase its earnings per share during its first 12 months.

“The federal government is increasingly requiring high-value solutions to improve healthcare IT practices and systems that will, in turn, contribute to the public health and safety of our nation’s citizens, ” said CACI President and CEO Dan Allen.

Allen added the company intends for the acquisition to expand its footprint in the healthcare information technology sector.

Emergint aims to help clients increase information exchange and interoperability in the healthcare arena, Emergint President and CEO Gil Delgado said.

The Louisville-based firm, founded in 1999 works with clients including the Centers for Disease Control and Prevention, the National Institutes of Health and the Food and Drug Administration.

Emergint’s 300 employees provide healthcare IT services to agencies including health data integration and analysis, data analytics, management and IT consulting and data and records management.

Investment bank KippsDeSanto advised Emergint in the transaction.

Check Also

F5 to Buy Shape Security for $1B; Francois Locoh-Donou Quoted

F5 Networks (Nasdaq: FFIV) has agreed to acquire Santa Clara, Calif.-based Shape Security for approximately $1B in cash as both companies aim to help government and enterprise customers secure digital experience with integrated offerings.

Paratek Secures $169M Anthrax Antibiotic Development Contract Under HHS Project BioShield

The Department of Health and Human Services has awarded Paratek Pharmaceuticals a potential a five-year, $169M contract to further develop an antibiotic drug as a potential treatment for inhalation anthrax.